{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:39:00Z","timestamp":1788910740658,"version":"build-2803163510"},"reference-count":87,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Hemophilia A (HA) is an inherited condition that is characterized by a lack of coagulation factor\nVIII (FVIII), which is needed for blood clotting. To produce Recombinant Factor VIII (rFVIII) for treatment,\ninnovative methods are required. This study presents a thorough examination of the genetic engineering and\nbiotechnological methods that are essential for the production of this complex process. Multiple host cells,\nsuch as animal, microbial, and human cell lines, are examined. Cultivating genetically modified cells enables\nthe production of rFVIII, with further changes after protein synthesis, such as glycosylation, taking place in eukaryotic\ncells to guarantee correct folding. The extraction and purification of rFVIII require advanced methods,\nincluding affinity chromatography, to improve the purity of the protein. The purified protein undergoes rigorous\nquality control, which includes Sodium Dodecyl-Sulfate Polyacrylamide Gel Electrophoresis (SDSPAGE)\nanalysis, to assess its identity, purity, and functioning. The scalability of this approach allows for the\nsynthesis of significant amounts of rFVIII for therapeutic purposes. Optimization strategies include modifying\nB-Domain-Deleted (BDD) FVIII, including introns in FVIII Complementary DNA (cDNA) sequences to\nboost synthesis and storage, and making changes to chaperone-binding areas to optimize protein release. Furthermore,\nthe search for a modified form of FVIII that has a longer duration of action in the body shows potential\nfor enhancing the effectiveness of synthetic FVIII and progressing the treatment of hemophilia A. Future\nresearch should focus on improving the treatment of hemophilia A by developing a variant of FVIII that has increased\nstability and reduced immunogenicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113816128327353241121050134","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:40:16Z","timestamp":1736926816000},"page":"1417-1429","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts"],"prefix":"10.2174","volume":"31","author":[{"given":"Amirhossein","family":"Ghaemi","sequence":"first","affiliation":[{"name":"School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Moghimi","sequence":"additional","affiliation":[{"name":"Department of Microbiology,\nSchool of Biology, College of Science, University of Tehran, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Hossein","family":"Sarrafzadeh","sequence":"additional","affiliation":[{"name":"School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/j.1538-7836.2005.01367.x","volume":"3","author":"Pipe S.W.","year":"2005","unstructured":"Pipe S.W.; The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost  2005,3(8),1692-1701","journal-title":"J Thromb Haemost"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1472-6750-11-114","volume":"11","author":"Swiech K.","year":"2011","unstructured":"Swiech K.; Kamen A.; Ansorge S.; Durocher Y.; Pican\u00e7o-Castro V.; Russo-Carbolante E.M.S.; Neto M.S.A.; Covas D.T.; Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII. BMC Biotechnol  2011,11(1),114","journal-title":"BMC Biotechnol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1566523033347417","volume":"3","author":"Saenko E.","year":"2003","unstructured":"Saenko E.; Ananyeva N.; Moayeri M.; Ramezani A.; Hawley R.; Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr Gene Ther  2003,3(1),27-41","journal-title":"Curr Gene Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1389203023380639","volume":"3","author":"Fuentes-Prior P.","year":"2002","unstructured":"Fuentes-Prior P.; Fujikawa K.; Pratt K.P.; New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci  2002,3(3),313-339","journal-title":"Curr Protein Pept Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/B978-0-12-801368-7.00002-8","author":"Wolfe L.C.","year":"2016","unstructured":"Wolfe L.C.; Hematologic Manifestations of Systemic Illness. Lanzkowsky's Manual of Pediatric Hematology and Oncology (Sixth Edition)  2016,7-31","journal-title":"Lanzkowsky's Manual of Pediatric Hematology and Oncology (Sixth Edition)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11274-005-9037-9","volume":"22","author":"Sarrafzadeh M.H.","year":"2006","unstructured":"Sarrafzadeh M.H.; Navarro J.M.; The effect of oxygen on the sporulation, \u03b4-endotoxin synthesis and toxicity of Bacillus thuringiensis H14. World J Microbiol Biotechnol  2006,22(3),305-310","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/bit.21201","volume":"97","author":"Ishaque A.","year":"2007","unstructured":"Ishaque A.; Thrift J.; Murphy J.E.; Konstantinov K.; Over-expression of Hsp70 in BHK-21 cells engineered to produce recombinant factor VIII promotes resistance to apoptosis and enhances secretion. Biotechnol Bioeng  2007,97(1),144-155","journal-title":"Biotechnol Bioeng"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1351-8216.2001.00133.x","volume":"8","author":"Giangrande P.L.F.","year":"2002","unstructured":"Giangrande P.L.F.; Safety and efficacy of KOGENATE  Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia  2002,8(Suppl. 2),19-22","journal-title":"Haemophilia"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/archinte.1989.00390060103022","volume":"149","author":"Brettler D.B.","year":"1989","unstructured":"Brettler D.B.; Forsberg A.D.; Levine P.H.; Louis M.; Kasper C.K.; Lusher J.M.; The use of porcine factor VIII concentrate (Hyate\u202f: C) in the treatment of patients With inhibitor antibodies to factor VIII a multicenter US experience. Arch Intern Med  1989,149(6),1381-1385","journal-title":"Arch Intern Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0002-9343(89)90274-X","volume":"86","author":"Green D.","year":"1989","unstructured":"Green D.; Tuite G.F.; Declining platelet counts and platelet aggregation during porcine VIII: C infusions. Am J Med  1989,86(2),222-224","journal-title":"Am J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18845\/tm.v29i4.3039","volume":"29","author":"Hern\u00e1ndez-Carvajal E.","year":"2017","unstructured":"Hern\u00e1ndez-Carvajal E.; Arce-Solano S.; Mena-Aguilar D.; Fuentes-Prior P.; Producci\u00f3n heter\u00f3loga y caracterizaci\u00f3n bioqu\u00edmica del procoagulante humano Factor VIII para ensayos de cristalizaci\u00f3n de macromol\u00e9culas proteicas. Tecnol Marcha  2017,29(4),78","journal-title":"Tecnol Marcha"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/ejh.13610","volume":"106","author":"Hermans C.","year":"2021","unstructured":"Hermans C.; Mancuso M.E.; Nolan B.; Pasi K.J.; Recombinant factor VIII Fc for the treatment of haemophilia A. Eur J Haematol  2021,106(6),745-761","journal-title":"Eur J Haematol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18388\/abp.2015_1056","volume":"63","author":"Mazurkiewicz-Pisarek A.","year":"2016","unstructured":"Mazurkiewicz-Pisarek A.; P\u0142ucienniczak G.; Ciach T.; P\u0142ucienniczak A.; The factor VIII protein and its function. Acta Biochim Pol  2016,63(1),11-16","journal-title":"Acta Biochim Pol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1182\/blood.V82.6.1767.1767","volume":"82","author":"Scandella BD.","year":"1993","unstructured":"Scandella BD.; Mattingly M.; Prescott R.; A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood  1993,82(6),1767-1775","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"12574","DOI":"10.1016\/S0021-9258(18)67127-3","volume":"261","author":"Burke R.L.","year":"1986","unstructured":"Burke R.L.; Pachl C.; Quiroga M.; Rosenberg S.; Haigwood N.; Nordfang O.; Ezban M.; The functional domains of coagulation factor VIII:C. J Biol Chem  1986,261(27),12574-12578","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1073\/pnas.83.16.5939","volume":"83","author":"Toole J.J.","year":"1986","unstructured":"Toole J.J.; Pittman D.D.; Orr E.C.; A large region (95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.  Proc Natl Acad Sci USA  1986,83,5939-5942","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1046\/j.1537-2995.2002.00221.x","volume":"42","author":"Bl\u00fcmel J.","year":"2002","unstructured":"Bl\u00fcmel J.; Schmidt I.; Effenberger W.; Seitz H.; Willkommen H.; Brackmann H.H.; L\u00f6wer J.; Eis-H\u00fcbinger A.M.; Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion  2002,42(11),1473-1481","journal-title":"Transfusion"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood.V94.10.3617.422a38f_3617_3617","volume":"94","author":"Yokozaki S.","year":"1999","unstructured":"Yokozaki S.; Fukuda Y.; Nakano I.; Katano Y.; Toyoda H.; Takamatsu J.; Detection of TT virus DNA in plasma-derived clotting factor concentrates. Blood  1999,94(10),3617","journal-title":"Blood"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1046\/j.1365-2516.1998.440628.x","volume":"4","author":"Lee C.A.","year":"1998","unstructured":"Lee C.A.; Kessler C.M.; Varon D.; Martinowitz U.; Heim M.; Evatt B.L.; Prions and haemophilia: Assessment of risk. Haemophilia  1998,4(4),628-633","journal-title":"Haemophilia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/DDDT.S85608","volume":"9","author":"Kannicht C.","year":"2015","unstructured":"Kannicht C.; Kohla G.; Tiemeyer M.; Walter O.; Sandberg H.; A new recombinant factor VIII: From genetics to clinical use. Drug Des Devel Ther  2015,9,3817-3819","journal-title":"Drug Des Devel Ther"},{"key":"ref=21","first-page":"104","volume":"4","author":"Yekta A.A.","year":"2006","unstructured":"Yekta A.A.; Zomorodipour A.; Khodabandeh M.; Daliri M.; Bacterial expression and purification of C1C2 domain of human factor VIII. Iran J Biotechnol  2006,4,104-111","journal-title":"Iran J Biotechnol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5045\/br.2015.50.2.103","volume":"50","author":"Choi S.J.","year":"2015","unstructured":"Choi S.J.; Jang K.J.; Lim J.A.; Kim H.S.; Human coagulation factor VIII domain-specific recombinant polypeptide expression. Blood Res  2015,50(2),103-108","journal-title":"Blood Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.V92.2.496","volume":"92","author":"Jacquemin M.G.","year":"1998","unstructured":"Jacquemin M.G.; Desqueper B.G.; Benhida A.; Vander Elst L.; Hoylaerts M.F.; Bakkus M.; Thielemans K.; Arnout J.; Peerlinck K.; Gilles J.G.G.; Vermylen J.; Saint-Remy J.M.R.; Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood  1998,92(2),496-506","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12896-017-0353-6","volume":"17","author":"Orlova N.A.","year":"2017","unstructured":"Orlova N.A.; Kovnir S.V.; Gabibov A.G.; Vorobiev I.I.; Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system. BMC Biotechnol  2017,17(1),33","journal-title":"BMC Biotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/bit.21057","volume":"95","author":"Sandberg H.","year":"2006","unstructured":"Sandberg H.; L\u00fctkemeyer D.; Kuprin S.; Wrangel M.; Almstedt A.; Persson P.; Ek V.; Mikaelsson M.; Mapping and partial characterization of proteases expressed by a CHO production cell line. Biotechnol Bioeng  2006,95(5),961-971","journal-title":"Biotechnol Bioeng"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15171\/bi.2017.23","volume":"7","author":"Mesgari-Shadi A.","year":"2017","unstructured":"Mesgari-Shadi A.; Sarrafzadeh M.H.; Osmotic conditions could promote scFv antibody production in the Escherichia coli HB2151. Bioimpacts  2017,7(3),199-206","journal-title":"Bioimpacts"},{"key":"ref=27","first-page":"26","volume":"7","author":"Haghi A.M.","year":"2012","unstructured":"Haghi A.M.; Nateghpour M.; Edrissian G.; Sepehrizadeh Z.; Mohebali M.; Khoramizade M.R.; Sequence analysis of different domains of Plasmodium vivax apical membrane antigen (PvAMA-1 gene) locus in Iran. Iran J Parasitol  2012,7(1),26-31","journal-title":"Iran J Parasitol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1016\/S0021-9258(18)68793-9","volume":"263","author":"Kaufman R.J.","year":"1988","unstructured":"Kaufman R.J.; Wasley L.C.; Dorner A.J.; Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem  1988,263(13),6352-6362","journal-title":"J Biol Chem"},{"key":"ref=29","author":"Cortes G.A.","year":"2023","unstructured":"Cortes G.A.; Moore M.J.; El-Nakeep S.; Physiology, Von Willebrand Factor. StatPearls  2023","journal-title":"StatPearls"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1055\/s-2001-16891","volume":"27","author":"Boedeker B.G.D.","year":"2001","unstructured":"Boedeker B.G.D.; Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost  2001,27(4),385-94","journal-title":"Semin Thromb Hemost"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S0887-7963(92)70177-1","volume":"6","author":"Boedeker B.G.D.","year":"1992","unstructured":"Boedeker B.G.D.; The manufacturing of the recombinant factor VIII, Kogenate. Transfus Med Rev  1992,6(4),256-260","journal-title":"Transfus Med Rev"},{"key":"ref=32","author":"Spier R.E.","year":"2013","unstructured":"Spier R.E.; Griffiths J.B.; Berthold W.; Production of recombinant factor VIII from perfusion cultures: I. Large scale fermentation. Animal Cell Technology: Products of Today, Prospects of Tomorrow  2013","journal-title":"Animal Cell Technology: Products of Today, Prospects of Tomorrow"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1055\/s-0037-1616092","volume":"86","author":"Plantier J.L.","year":"2001","unstructured":"Plantier J.L.; Rodriguez M.H.; Enjolras N.; Attali O.; N\u00e9grier C.; A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII. Thromb Haemost  2001,86(8),596-603","journal-title":"Thromb Haemost"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/mt.2010.239","volume":"19","author":"Spencer H.T.","year":"2011","unstructured":"Spencer H.T.; Denning G.; Gautney R.E.; Dropulic B.; Roy A.J.; Baranyi L.; Gangadharan B.; Parker E.T.; Lollar P.; Doering C.B.; Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther  2011,19(2),302-309","journal-title":"Mol Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1074\/jbc.M312451200","volume":"279","author":"Doering C.B.","year":"2004","unstructured":"Doering C.B.; Healey J.F.; Parker E.T.; Barrow R.T.; Lollar P.; Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem  2004,279(8),6546-6552","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2003-11-3891","volume":"104","author":"Parker E.T.","year":"2004","unstructured":"Parker E.T.; Healey J.F.; Barrow R.T.; Craddock H.N.; Lollar P.; Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood  2004,104(3),704-710","journal-title":"Blood"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1160\/TH08-12-0818","volume":"102","author":"Healey J.F.","year":"2009","unstructured":"Healey J.F.; Parker E.T.; Barrow R.T.; Langley T.J.; Church W.R.; Lollar P.; The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost  2009,102(7),35-41","journal-title":"Thromb Haemost"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fmicb.2015.00242","volume":"6","author":"Shintani M.","year":"2015","unstructured":"Shintani M.; Sanchez Z.K.; Kimbara K.; Genomics of microbial plasmids: classification and identification based on replication and transfer systems and host taxonomy. Front Microbiol  2015,6,242","journal-title":"Front Microbiol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/pro.5560041120","volume":"4","author":"Pace C.N.","year":"1995","unstructured":"Pace C.N.; Vajdos F.; Fee L.; Grimsley G.; Gray T.; How to measure and predict the molar absorption coefficient of a protein. Protein Sci  1995,4(11),2411-2423","journal-title":"Protein Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.32607\/20758251-2012-4-1-93-100","volume":"4","author":"Orlova N.A.","year":"2012","unstructured":"Orlova N.A.; Kovnir S.V.; Vorobiev I.I.; Yuriev A.S.; Gabibov A.G.; Vorobiev A.I.; Stable expression of recombinant factor VIII in CHO cells using methotrexate-driven transgene amplification. Acta Nat (Engl Ed)  2012,4(1),93-100","journal-title":"Acta Nat (Engl Ed)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1472-6750-14-56","volume":"14","author":"Orlova N.A.","year":"2014","unstructured":"Orlova N.A.; Kovnir S.V.; Hodak J.A.; Vorobiev I.I.; Gabibov A.G.; Skryabin K.G.; Improved elongation factor-1 alpha-based vectors for stable high-level expression of heterologous proteins in Chinese hamster ovary cells. BMC Biotechnol  2014,14(1),56","journal-title":"BMC Biotechnol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"D332","DOI":"10.1093\/nar\/gkl828","volume":"35","author":"Gregory T.R.","year":"2007","unstructured":"Gregory T.R.; Nicol J.A.; Tamm H.; Kullman B.; Kullman K.; Leitch I.J.; Eukaryotic genome size databases. Nucleic Acids Res  2007,35,D332-8","journal-title":"Nucleic Acids Res"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/ph6050579","volume":"6","author":"Lai T.","year":"2013","unstructured":"Lai T.; Yang Y.; Ng SK.; Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals  2013,6(5),579-603","journal-title":"Pharmaceuticals"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/medicina59040694","volume":"59","author":"Bashar S.","year":"2023","unstructured":"Bashar S.; Jeong H.J.; Bacterial production of recombinant coagulation factor VIII domains. Medicina (Kaunas)  2023,59(4),694","journal-title":"Medicina (Kaunas)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/nbt1110-1153","volume":"28","author":"Bosques C.J.","year":"2010","unstructured":"Bosques C.J.; Collins B.E.; Meador J.W.; Sarvaiya H.; Murphy J.L.; DelloRusso G.; Bulik D.A.; Hsu I.H.; Washburn N.; Sipsey S.F.; Myette J.R.; Raman R.; Shriver Z.; Sasisekharan R.; Venkataraman G.; Chinese hamster ovary cells can produce galactose-\u03b1-1,3-galactose antigens on proteins. Nat Biotechnol  2010,28(11),1153-1156","journal-title":"Nat Biotechnol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e43394","DOI":"10.1371\/journal.pone.0043394","volume":"7","author":"Dietmair S.","year":"2012","unstructured":"Dietmair S.; Hodson M.P.; Quek L-E.; Timmins N.E.; Gray P.; Nielsen L.K.; A multi-omics analysis of recombinant protein production in Hek293 cells. PLoS One  2012,7(8),e43394","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5661\/bger-28-147","volume":"28","author":"Ghaderi D.","year":"2012","unstructured":"Ghaderi D.; Zhang M.; Hurtado-Ziola N.; Varki A.; Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev  2012,28(1),147-176","journal-title":"Biotechnol Genet Eng Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/nbt1026","volume":"22","author":"Wurm F.M.","year":"2004","unstructured":"Wurm F.M.; Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol  2004,22(11),1393-1398","journal-title":"Nat Biotechnol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.copbio.2014.06.010","volume":"30","author":"Butler M.","year":"2014","unstructured":"Butler M.; Spearman M.; The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol  2014,30,107-112","journal-title":"Curr Opin Biotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1008170710003","volume":"32","author":"Barnes L.M.","year":"2000","unstructured":"Barnes L.M.; Bentley C.M.; Dickson A.J.; Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology  2000,32(2),109-123","journal-title":"Cytotechnology"},{"key":"ref=51","year":"2013","unstructured":"Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology, Annex 3, TRS No 814.  Available from:  https:\/\/www.who.int\/publications\/m\/item\/annex3-who-trs-8142013"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nbt1097-971","volume":"15","author":"Paleyanda R.K.","year":"1997","unstructured":"Paleyanda R.K.; Velander W.H.; Lee T.K.; Scandella D.H.; Gwazdauskas F.C.; Knight J.W.; Hoyer L.W.; Drohan W.N.; Lubon H.; Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol  1997,15(10),971-975","journal-title":"Nat Biotechnol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0378-4320(03)00169-6","volume":"79","author":"Niemann H.","year":"2003","unstructured":"Niemann H.; Kues W.A.; Application of transgenesis in livestock for agriculture and biomedicine. Anim Reprod Sci  2003,79(3-4),291-317","journal-title":"Anim Reprod Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/07853899209149954","volume":"24","author":"J\u00e4nne J.","year":"1992","unstructured":"J\u00e4nne J.; Hyttinen J.M.; Peura T.; Tolvanen M.; Alhonen L.; Halmekyt\u00f6 M.; Transgenic animals as bioproducers of therapeutic proteins. Ann Med  1992,24(4),273-280","journal-title":"Ann Med"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-0-387-74087-4_15","volume":"606","author":"B\u00f6sze Z.","year":"2008","unstructured":"B\u00f6sze Z.; Baranyi M.; Bruce C.; Whitelaw A.; Producing recombinant human milk proteins in the milk of livestock species. Adv Exp Med Biol  2008,606,357-395","journal-title":"Adv Exp Med Biol"},{"key":"ref=56","first-page":"s627","volume":"38","author":"Murray J.D.","year":"2010","unstructured":"Murray J.D.; Mohamad-Fauzi N.; Cooper C.A.; Maga E.A.; Current status of transgenic animal research for human health applications. Acta Sci Vet  2010,38,s627-s632","journal-title":"Acta Sci Vet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.anireprosci.2004.04.010","volume":"82-83","author":"Keefer C.L.","year":"2004","unstructured":"Keefer C.L.; Production of bioproducts through the use of transgenic animal models. Anim Reprod Sci  2004,82-83,5-12","journal-title":"Anim Reprod Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0093-691X(99)00247-2","volume":"53","author":"Brink M.F.","year":"2000","unstructured":"Brink M.F.; Bishop M.D.; Pieper F.R.; Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk. Theriogenology  2000,53(1),139-148","journal-title":"Theriogenology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nbt0502-484","volume":"20","author":"van Berkel P.H.C.","year":"2002","unstructured":"van Berkel P.H.C.; Welling M.M.; Geerts M.; van Veen H.A.; Ravensbergen B.; Salaheddine M.; Pauwels E.K.J.; Pieper F.; Nuijens J.H.; Nibbering P.H.; Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol  2002,20(5),484-487","journal-title":"Nat Biotechnol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1600-0609.2012.01804.x","volume":"89","author":"Casademunt E.","year":"2012","unstructured":"Casademunt E.; Martinelle K.; Jernberg M.; Winge S.; Tiemeyer M.; Biesert L.; Knaub S.; Walter O.; Schr\u00f6der C.; The first recombinant human coagulation factor VIII of human origin: Human cell line and manufacturing characteristics. Eur J Haematol  2012,89(2),165-176","journal-title":"Eur J Haematol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","volume":"65","author":"Bj\u00f6rkman S.","year":"2009","unstructured":"Bj\u00f6rkman S.; Folkesson A.; J\u00f6nsson S.; Pharmacokinetics and dose requirements of factor VIII over the age range 3\u201374 years. Eur J Clin Pharmacol  2009,65(10),989-998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1111\/jth.12929","volume":"13","author":"Tiede A.","year":"2015","unstructured":"Tiede A.; Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost  2015,13(Suppl. 1),S176-S179","journal-title":"J Thromb Haemost"},{"key":"ref=63","first-page":"86","volume":"45","author":"Graf L.","year":"2018","unstructured":"Graf L.; Extended half-life factor VIII and factor IX preparations. Transfusion Medicine and Hemotherapy. S. Karger AG Basel, Switzerland  2018,45,86-91","journal-title":"Karger AG Basel, Switzerland"},{"key":"ref=64","first-page":"3031","volume":"119","author":"Powell J.S.","year":"2012","unstructured":"Powell J.S.; Josephson N.C.; Quon D.; Ragni M.V.; Cheng G.; Li E.; Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, The Journal of the American Society of Hematology. American Society of Hematology Washington, DC  2012,119,3031-3037","journal-title":"American Society of Hematology Washington, DC"},{"key":"ref=65","first-page":"317","volume":"123","author":"Mahlangu J.","year":"2014","unstructured":"Mahlangu J.; Powell J.S.; Ragni M.V.; Chowdary P.; Josephson N.C.; Pabinger I.; Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, The Journal of the American Society of Hematology. American Society of Hematology Washington, DC  2014,123,317-325","journal-title":"American Society of Hematology Washington, DC"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biologicals.2015.05.012","volume":"43","author":"McCue J.","year":"2015","unstructured":"McCue J.; Kshirsagar R.; Selvitelli K.; Lu Q.; Zhang M.; Mei B.; Peters R.; Pierce G.F.; Dumont J.; Raso S.; Reichert H.; Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals  2015,43(4),213-219","journal-title":"Biologicals"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.copbio.2021.06.027","volume":"71","author":"Morris C.","year":"2021","unstructured":"Morris C.; Lee Y.S.; Yoon S.; Adventitious agent detection methods in bio-pharmaceutical applications with a focus on viruses, bacteria, and mycoplasma. Curr Opin Biotechnol  2021,71,105-114","journal-title":"Curr Opin Biotechnol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14653240701656053","volume":"9","author":"Pican\u00e7o V.","year":"2007","unstructured":"Pican\u00e7o V.; Heinz S.; Bott D.; Behrmann M.; Covas D.T.; Seifried E.; Tonn T.; Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter. Cytotherapy  2007,9(8),785-794","journal-title":"Cytotherapy"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jth.12412","volume":"12","author":"Shahani T.","year":"2014","unstructured":"Shahani T.; Covens K.; Lavend\u2019homme R.; Jazouli N.; Sokal E.; Peerlinck K.; Jacquemin M.; Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost  2014,12(1),36-42","journal-title":"J Thromb Haemost"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s10529-012-0925-4","volume":"34","author":"da Rosa N.G.","year":"2012","unstructured":"da Rosa N.G.; Swiech K.; Pican\u00e7o-Castro V.; de Sousa Russo-Carbolante E.M.; Neto M.A.S.; de Castilho-Fernandes A.; Fa\u00e7a V.M.; Fontes A.M.; Covas D.T.; SK-HEP cells and lentiviral vector for production of human recombinant factor VIII. Biotechnol Lett  2012,34(8),1435-1443","journal-title":"Biotechnol Lett"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4939-7312-5_5","volume":"1674","year":"2018","unstructured":"Fantacini DM, Pican\u00e7o-Castro V. Production of Recombinant Factor VIII in Human Cell Lines. Methods Mol Bio  2018,1674,63-74","journal-title":"Methods Mol Bio"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.3390\/jcm10245959","volume":"10","author":"Kenet G.","year":"2021","unstructured":"Kenet G.; Chen Y.C.; Lowe G.; Percy C.; Tran H.; von Drygalski A.; Trossa\u00ebrt M.; Reding M.; Oldenburg J.; Mingot-Castellano M.E.; Park Y.S.; Peyvandi F.; Ozelo M.C.; Mahlangu J.; Quinn J.; Huang M.; Reddy D.B.; Kim B.; Real-world rates of bleeding, factor viii use, and quality of life in individuals with severe haemophilia a receiving prophylaxis in a prospective, noninterventional study. J Clin Med  2021,10(24),5959","journal-title":"J Clin Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/21655979.2017.1279767","volume":"8","author":"Swiech K.","year":"2017","unstructured":"Swiech K.; Pican\u00e7o-Castro V.; Covas D.T.; Production of recombinant coagulation factors: Are humans the best host cells? Bioengineered  2017,8(5),462-470","journal-title":"Bioengineered"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","volume":"137","author":"Callaghan M.U.","year":"2021","unstructured":"Callaghan M.U.; Negrier C.; Paz-Priel I.; Chang T.; Chebon S.; Lehle M.; Mahlangu J.; Young G.; Kruse-Jarres R.; Mancuso M.E.; Niggli M.; Howard M.; Bienz N.S.; Shima M.; Jim\u00e9nez-Yuste V.; Schmitt C.; Asikanius E.; Levy G.G.; Pipe S.W.; Oldenburg J.; Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood  2021,137(16),2231-2242","journal-title":"Blood"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood-2018-99-118492","volume":"132","author":"Paz-Priel I.","year":"2018","unstructured":"Paz-Priel I.; Chang T.; Asikanius E.; Chebon S.; Emrich T.; Fernandez E.; Kuebler P.; Schmitt C.; Immunogenicity of emicizumab in people with hemophilia a (PwHA): Results from the HAVEN 1-4 studies. Blood  2018,132(Suppl. 1),633","journal-title":"Blood"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1111\/hae.14421","volume":"27","author":"Parnes A.","year":"2021","unstructured":"Parnes A.; Mahlangu J.N.; Pipe S.W.; Paz-Priel I.; Lehle M.; Trask P.C.; Jim\u00e9nez-Yuste V.; Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Haemophilia  2021,27(6),e772-e775","journal-title":"Haemophilia"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood.V130.Suppl_1.86.86","volume":"130","author":"Jimenez-Yuste V.","year":"2017","unstructured":"Jimenez-Yuste V.; Shima M.; Fukutake K.; Lehle M.; Chebon S.; Retout S.; Portron A.; Levy G.G.; Emicizumab subcutaneous dosing every 4 weeks for the management of hemophilia A: Preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4). Blood  2017,130(Suppl. 1),86","journal-title":"Blood"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2022-157264","volume":"140","author":"Pipe S.W.","year":"2022","unstructured":"Pipe S.W.; Collins P.; Dhalluin C.; Kenet G.; Schmitt C.; Buri M.; Jim\u00e9nez-Yuste V.; Peyvandi F.; Young G.; Oldenburg J.; Mancuso M.E.; Kiialainen A.; Chang T.; Lehle M.; Fijnvandraat K.; Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: Results from the interim analysis of the HAVEN 7 study.  Blood  2022,140(Suppl. 1),457-459","journal-title":"Blood"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2023-177963","volume":"142","author":"Pipe S.","year":"2023","unstructured":"Pipe S.; Collins P.; Dhalluin C.; Kenet G.; Schmitt C.; Buri M.; Jim\u00e9nez-Yuste V.; Peyvandi F.; Young G.; Oldenburg J.; Mancuso M.E.; Kavakli K.; Kiialainen A.; Chang T.; Lehle M.; Niggli M.; Fijnvandraat K.; Emicizumab prophylaxis in infants with severe hemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 7 study. Blood  2023,142(Suppl. 1),505","journal-title":"Blood"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1182\/blood.2023021832","volume":"143","author":"Pipe S.W.","year":"2024","unstructured":"Pipe S.W.; Collins P.; Dhalluin C.; Kenet G.; Schmitt C.; Buri M.; Jim\u00e9nez-Yuste V.; Peyvandi F.; Young G.; Oldenburg J.; Mancuso M.E.; Kavakli K.; Kiialainen A.; Deb S.; Niggli M.; Chang T.; Lehle M.; Fijnvandraat K.; Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): Primary analysis of a phase 3b open-label trial. Blood  2024,143(14),1355-1364","journal-title":"Blood"},{"key":"ref=81","first-page":"T-07","volume":"44","author":"Oldenburg J.","year":"2024","unstructured":"Oldenburg J.; Pipe S.W.; Collins P.; Dhalluin C.; Kenet G.; Schmitt C.; Emicizumab prophylaxis for the treatment of infants with severe haemophilia a without factor viii inhibitors: Primary analysis of the HAVEN 7 study. Hamostaseologie  2024,44,T-07","journal-title":"Hamostaseologie"},{"key":"ref=82","first-page":"142","volume":"20","author":"Zhou M.","year":"2020","unstructured":"Zhou M.; Hu Z.; Zhang C.; Wu L.; Li Z.; Liang D.; Gene therapy for hemophilia A: Where we stand. Current Gene Therapy. Bentham Science Publishers  2020,20(2),142-151","journal-title":"Bentham Science Publishers"},{"key":"ref=83","first-page":"887","volume":"119","author":"Miesbach W.","year":"2022","unstructured":"Miesbach W.; Klamroth R.; Oldenburg J.; Tiede A.; Gene therapy for hemophilia\u2014opportunities and risks. Deutsches \u00c4rzteblatt International. Deutscher Arzte-Verlag GmbH  2022,119,887","journal-title":"Deutscher Arzte-Verlag GmbH"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"Nathwani A.C.","year":"2022","unstructured":"Nathwani A.C.; Gene therapy for hemophilia. Hematology (Am Soc Hematol Educ Program)  2022,2022(1),569-578","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=85","first-page":"1013","volume":"386","author":"Ozelo M.C.","year":"2022","unstructured":"Ozelo M.C.; Mahlangu J.; Pasi K.J.; Giermasz A.; Leavitt A.D.; Laffan M.; Valoctocogene roxaparvovec gene therapy for hemophilia A. New England Journal of Medicine. Mass Medical Soc  2022,386,1013-1025","journal-title":"Mass Medical Soc"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1182\/blood-2021-148651","volume":"138","author":"Visweshwar N.","year":"2021","unstructured":"Visweshwar N.; Harrington T.J.; Leavitt A.D.; Konkle B.A.; Giermasz A.; Stine K.; Rupon J.; Di Russo G.; Tseng L-J.; de los Angeles Resa M.; Ganne F.; Agathon D.; Plonski F.; Rouy D.; Cockroft B.M.; Fang A.; Arkin S.; Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A. Blood  2021,138(Suppl. 1),564","journal-title":"Blood"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1182\/blood-2021-148661","volume":"138","author":"Pipe S.W.","year":"2021","unstructured":"Pipe S.W.; Sheehan J.P.; Coppens M.; Eichler H.; Linardi C.; Wiegmann S.; Hay C.R.M.; Lissitchkov T.; First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years. Blood  2021,138(Suppl. 1),3971","journal-title":"Blood"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128327353241121050134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238318\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128327353241121050134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T14:47:38Z","timestamp":1748962058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238318\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":87,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128327353241121050134","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}